NCT06724289View on ClinicalTrials.gov

Psilocybin for Prolonged Grief Disorder

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

October 31, 2026

Conditions
Prolonged Grief Disorder
Interventions
DRUG

Psilocybin 25 mg

25 mg psilocybin administered to each participant in single arm, open-label trial

Trial Locations (1)

22903

University of Virginia, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER